Pancreatic ductal adenocarcinoma, one of medicine's most stubborn adversaries, has long resisted treatment not merely through brute biology but through a kind of metabolic cunning—and a new review in Current Molecular Pharmacology illuminates how lactate, a molecule the body generates routinely, has been co-opted by tumors as a tool of growth, immune evasion, and epigenetic manipulation. The process of lactylation—in which lactate chemically modifies proteins to alter their behavior—emerges as a central mechanism by which pancreatic cancer reshapes its own neighborhood into a fortress hostile
News-Medical
· Jun 26, 2026
· health
· 1 min de leitura
High
Apuração: Verificado
Lactate and lactylation emerge as key drivers in pancreatic cancer progression
Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies, motivating urgent development of new therapeutic approaches.
◉
Health & Medicine
8525 artigos relacionados
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 99% correspondência
Cobertura Relacionada
BBC News · Aug 27
Facebook horse seller ordered to pay damages after selling unfit animals to buyers
Five women report being mis-sold unsafe or injured horses by a Facebook seller, with one buyer's daughter suffering a se…
Al Jazeera · Aug 27 Pakistan hospital fire kills 14 infants; families demand accountabilityFourteen babies died in a fire at Islamabad's Institute of Medical Sciences. Grieving families accuse hospital staff and…
Peter Attia MD · Aug 27 GLP-1 drugs show promise beyond metabolism, but questions remain about whyGLP-1 medications, originally developed for type 2 diabetes, now show potential benefits across metabolic and non-metabo…
Korea JoongAng Daily · Aug 27 Korean researchers identify Erbb4 protein as potential Alzheimer's breakthroughKorean researchers identified the Erbb4 protein as a key driver of Alzheimer's progression, showing it triggers synapse …
Viés e Enquadramento
⚖
Scientific review article presents balanced assessment of lactate/lactylation in pancreatic cancer with acknowledgment of both promising preclinical findings and clinical translation challenges.
Bias Direction
center
Confidence
HIGH
Objective scientific reporting with balanced presentation of mechanisms, therapeutic potential, and limitations. Uses cautious language ('illuminate,' 'emerge,' 'promise') appropriate for medical research communication.
pivotal, multifaceted roles
orchestrates multicellular communication
formidable desmoplastic barrier
foundational framework
Patient or clinical perspective on treatment outcomes
Cost-effectiveness or accessibility considerations for proposed therapies
Comparative efficacy data versus existing pancreatic cancer treatments
Perspectives from researchers with competing therapeutic approaches
Impacto Geopolítico
🌎
This is a medical research article about pancreatic cancer biology, not a geopolitical event. No international implications or power dynamics exist.
Escalation Risk
N/A
Confidence
HIGH
Lente Econômica
📈
Research identifies lactate and lactylation as key drivers of pancreatic cancer progression, with emerging therapeutic targets showing promise but facing significant clinical translation challenges and toxicity concerns.
Market Signal
mixed
Confidence
MED
Pharmaceutical and Biotechnology
Oncology/Cancer Treatment
Medical Devices and Diagnostics
Healthcare Services
Patients with pancreatic cancer may eventually benefit from new targeted therapies, though clinical availability remains years away. Healthcare costs could increase if combination therapies become standard treatment protocols. Patient outcomes may improve if clinical translation succeeds, but accessibility and affordability of novel treatments remain uncertain.
FDA may need to establish expedited review pathways for combination lactate-targeting therapies given pancreatic cancer's poor prognosis. Healthcare systems should prepare for potential integration of metabolic profiling into cancer diagnostics. Regulatory frameworks may need updating to address systemic toxicity monitoring for LDHA and MCT inhibitors. Research funding agencies may prioritize spatial transcriptomics and precision oncology infrastructure.